Abstract
Red cells can be labelled with peptides from the SARS-CoV-2 spike protein and used for serologic screening of SARS-CoV-2 antibodies. We evaluated 140 convalescent COVID-19 patients and 275 healthy controls using this C19-kodecyte assay. The analytical performance of the new assay was compared with a virus neutralizing assay and 2 commercial chemiluminescent antibody tests (Total assay and IgG assay, Ortho). The C19-kodecyte assay detected SARS-CoV-2 antibodies with a sensitivity of 92.8% and specificity of 96.3%, well within the minimum performance range required by FDA for EUA authorization of serologic tests. The Cohen’s kappa coefficient was 0.90 indicating an almost perfect agreement with the Total assay. The Pearson correlation coefficient was 0.20 with the neutralizing assay (0.49 with IgG, and 0.41 with Total assays). The limited correlation in assay reaction strengths suggested that the assays may detect different antibody specificities. Our easily scalable C19-kodecyte assay may vastly improve test capacity in blood typing laboratories using their routine setups for column agglutination technique.
Competing Interest Statement
SMH and NVB are employees and stockholders in Kode Biotech, the patent owner of Kode biosurface engineering technology. MRH performed this work as an employee of Laulima Government Solutions LLC, Orlando, FL. All other authors declared having no competing financial interest.
Funding Statement
This work was supported in whole or in part by the Intramural Research Program (project ID ZIC CL002128) of the NIH Clinical Center at the National Institutes of Health; National Institute of Allergy and Infectious Diseases, National Institutes of Health, U.S. Department of Health and Human Services (DHHS), under Contract No. HHSN272201800013C; and by the New Zealand Ministry of Business, Innovation & Employment COVID-19 Innovation Acceleration Fund, contract CIAF 0490.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
for all 3 clinical trials NCT04360278, NCT00001846 and NCT00067054: 1. Institutional Review Boards that ruled on ethics of your study: NIH Institutional Review Board (IRB), National Institutes of Health, Bethesda MD 2. Decisions made: ethical approvals were given for all 3 clinical trials. Institutional Review Board (IRB) approved protocols were NCT04360278, NCT00001846 and NCT00067054, respectively, which entailed written informed consent. The plasma controls from 2008 were collected under the Vaccine Research Center (VRC), National Institutes of Allergy and Infectious Diseases (NIAID), National Institutes of Health sample collection protocol VRC 200 (NCT00067054) in compliance with the NIH IRB approved procedures. All subjects met protocol eligibility criteria and agreed to participate in the study by signing the NIH IRB approved informed consent. Research studies with these samples were conducted by protecting the rights and privacy of the study participants.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of interest disclosure: SMH and NVB are employees and stockholders in Kode Biotech, the patent owner of Kode biosurface engineering technology. MRH performed this work as an employee of Laulima Government Solutions, LLC (Orlando, FL). All other authors declared having no competing financial interest.
Statement of Disclaimer: The views expressed do not necessarily represent the view of the National Institutes of Health, the US Food and Drug Administration, the Department of Health and Human Services, or the U.S. Federal Government.
Data Availability
data as documented in the manuscript and supplement
